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Abstract 
 
Chemotherapy for pancreatic cancer is hampered by the tumor physio-pathological 
complexity. Here we show a targeted nanomedicine using a new ligand, the CKAAKN 
peptide, which had been identified by phage display, as an efficient homing device within the 
pancreatic pathological microenvironment. Taking advantage of the squalenoylation platform, 
the CKAAKN peptide was conjugated to squalene (SQCKAAKN) and then co-nanoprecitated 
with the squalenoyl prodrug of gemcitabine (SQdFdC) giving  near monodisperse 
nanoparticles (NPs) for safe intravenous injection. By interacting with a novel target pathway, 
the Wnt-2, the CKAAKN functionalization enabled nanoparticles: (i) to specifically interact 
with both tumor cells and angiogenic vessels and (ii) to simultaneously promote pericyte 
coverage, thus leading to the normalization of the vasculature likely improving the tumor 
accessibility for the therapy.  All together, this approach represents a unique targeted 
nanoparticle design with remarkable selectivity towards pancreatic cancer and multiple 
mechanism of action.  
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Introduction 
 
Pancreatic cancer is a devastating disease which represents the fourth leading cause of 
cancer-related death in the European Community and in North America [1]. The median 
survival is less than 6 months and the maximum is 5 years for 6% of patients [2]. Despite this 
high mortality, pancreatic cancer represents only the 10
th
 most common cause of new cancers. 
This imbalance between frequency and mortality is because most patients are diagnosed at an 
unresectable, advanced and metastatic stage for which, at the moment, only palliative 
treatments are available, due to the lack of sensitivity of pancreatic cancer to many 
chemotherapeutic drugs [2]. Despite the decline over the past decade in the global mortality 
related to lung, colon, prostate and breast cancer, the progresses in pancreatic cancer therapy 
had remained exceedingly slow and disappointing without impairing the death rate. Since 
1996, gemcitabine (dFdC), a nucleoside analogue that blocks DNA replication, has been the 
major chemotherapic agent for pancreatic cancer treatment [2]. Despite its weak response rate 
of 5% and the modest overall survival benefit, this drug still remains the first-line treatment in 
the clinical practice.  
Several combined protocol therapies with gemcitabine have been tested in 
randomized clinical trials [3, 4]. Only erlotinib, an inhibitor of the epidermal growth 
factor receptor and recently (September 2013) Abraxane (paclitaxel albumin-bound 
nanoparticles) have been approved by the FDA in combination with gemcitabine due to 
the significant improvement in patient survival and delay in tumor growth [5-7]. Due to 
its rather hydrophilic character, gemcitabine is unable to passively diffuse across the plasma 
membrane but it is transported into the cell by either human equilibrative (hENT) or sodium-
gradient nucleoside transporters. The resistance to gemcitabine treatment often arises from the 
down regulation of these nucleoside transporters which impairs gemcitabine membrane 
transport, as shown in both the pre-clinical experimental models and the clinic [8]. 
Gemcitabine is also rapidly inactivated into the blood, due to the fast metabolization by blood 
deaminases, into the inactive difluorouracil. Thus, a frequent administration schedule at a high 
drug dose (usually 800-1000 mg/m
2
, 30 min infusion) is required. Additionally, the poor 
tumor tissue perfusion resulting from deprived vascularization, the formation of a dense 
stroma and the important heterogeneity of pancreatic cancer cells dramatically hamper drug 
efficacy and bioavailability in the tumor tissue, also leading to significant side effects [9].  
Drug nanocarriers decorated with hydrophilic and flexible polymers, such as 
poly(ethylene glycol) (PEG), have been proposed to improve drug accumulation at the tumor 
target site through the so-called Enhanced Permeability and Retention (EPR) effect that takes 
advantage of the highly irregular tumor vasculature with abnormal heterogeneous density, the 
large pores on the endothelial walls and the reduced lymphatic drainage in tumor tissue [10, 
11]. However in several tumors, such passive targeting is inefficient. Therefore, the 
development of targeted therapeutic approaches, using nanoparticles (NPs) able to specifically 
bind to receptors mainly expressed onto malignant cells and relatively down regulated in 
healthy ones [12], represents an attractive therapeutic alternative [13-15]. To date, there are 
very few examples of drug-loaded nanoparticles functionalized with specific ligands showing 
a therapeutic efficacy in experimental pancreatic cancer models. For instance, nanocarriers 
were decorated with the epidermal growth factor receptor (EGFR) [16], the arginine-glycine-
aspartic acid (RGD) peptide [17] or an antibody towards the transferrin receptor [18]. 
However, apart from the fact that these nanodevices exhibited poor drug loading [17, 18] they 
were functionalized with homing devices not specific for pancreatic cancer since typically 
expressed also on several other types of healthy and/or cancer cells. This explains the inability 
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of these materials to reach the pancreatic cancer tissue, even at a low concentration 
[19].Therefore, the discovery of more specific ligands for pancreatic tumor targeting is 
urgently needed and represents an important challenge. 
In this context, we have taken advantage of previous findings that, starting from a 
phage-displayed peptide library screening on mouse models of cancer, described peptides that 
selectively bind tumor vasculature [20]. The main advantage of this approach consists in the 
identification of novel peptide ligands, able to specifically interact with the target disease 
marker proteins, which are accessible via the systemic circulation within a definite 
pathological microenvironment. In particular Joyce et al. [20] identified a linear peptide 
composed by 6 aminoacids (i.e. CKAAKN) which specifically bound tumor vessels in the 
RIP-Tag2 transgenic mice, a prototypical mouse model of multistage pancreatic islet cell 
carcinoma [20, 21]. 
Motivated by this findings, we have constructed a novel efficient targeted 
nanomedicine for pancreatic cancer treatment, using squalene, a natural and biocompatible 
lipid as carrier material [21], gemcitabine as anticancer drug and the CKAAKN peptide as 
homing device. After chemical modification, the squalene was conjugated to either 
gemcitabine (SQdFdC) or to CKAAKN peptide (SQCKAAKN). 
 
 
 
1. Materials and methods 
 
1.1. Materials 
1,1',2-Trisnor-squalenic aldehyde was obtained from squalene as previously described 
[21]. Gemcitabine hydrochloride (difluorodeoxycytidine (dFdC)) was purchased from 
Sequoia Research Products Ltd (UK). 4-(N)-trisnorsqualenoyl-gemcitabine (SQdFdC) was 
obtained as previously reported [22]. CKAAKN peptide was purchased from CASLO 
Laboratory Aps (Denmark). Squalene, dextrose and all other reagents were obtained by 
Sigma-Aldrich Chemical (Italy). All solvents were of analytical grade from Carlo Erba 
Reagenti (Italy) or VWR (France). The 
1
H NMR and 
13
C NMR spectra were recorded on 
Bruker Avance 300 (300 MHz, 75 MHz) or Bruker Avance 400 (400 MHz, 100 MHz) 
spectrometers in CDCl3, CD3COCD3, CD3OD or D2O. Multiplicities of resonances are 
described as broad (b), singlet (s), doublet (d), triplet (t), or multiplet (m). Recognition of 
methyl, methylene, methine, and quaternary carbon nuclei in 
13
C NMR spectra rests on the J-
modulated spin-echo sequence. Mass spectra were obtained using electrospray ionization 
(ESI) conditions in a positive-ion or a negative-ion mode either on Finnigan-MAT TSQ 700 
spectrometer (CA) or Esquire LC Bruker spectrometers. All reactions involving air- or water-
sensitive compounds were routinely conducted in glassware which was flame-dried under a 
positive pressure of nitrogen. The reactions were monitored by thin-layer chromatography 
(TLC) on F254 silica gel pre-coated plates. After development, the plates were viewed under 
UV light (254 nm) and visualized with I2 or Kägi-Misher reagents. Flash-column 
chromatography was performed on CombiFlash
®
 Rf systems (Teledyne ISCO, Italy) on 
appropriate columns (silica or RP18). All solvents were distilled prior to flash 
chromatography. 
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1.2. Synthesis and characterization of 6-(maleimidyl)-hexanoic acid (trisnor-
squalenylidene)-hydrazide (9) 
A solution of 1,1’,2-trisnor-squalenic aldehyde (8) (0.334 g, 0.868 mmol) in CH2Cl2 was 
added to dry methanol (15 mL). The resulting mixture was sonicated few minutes until 
complete dissolution. [6-(maleimido)hexanamido]azanium trifluoroacetate (7) [23] (0.306 g, 
0.868 mmol) and 4 Å molecular sieves (200 mg) were then added and the reaction mixture 
was stirred for 1 h at room temperature under nitrogen. The formation of the desired product 
(9) was monitored by TLC (petroleum ether/ethyl acetate 1/1 v/v, Rf: 0.65). The mixture was 
filtered and concentrated under reduced pressure. The residue was taken into water (5 mL) 
and extracted with CH2Cl2 (3 x 15 mL). The combined organic phases were dried over 
anhydrous MgSO4 and concentrated in vacuo. Purification by flash-chromatography on silica 
column, eluting with a gradient of petroleum ether to petroleum ether/ethyl acetate 60/40 v/v, 
gave the product as a light yellow waxy material (0.211 g, 63% yield) (Supplementary 
material, Figure S1). 
1
H NMR (CDCl3) δ: 8.39 (s, 1H, CH=NN), 7.05 (t, J = 5.2 Hz, 1H, NHCO), 6.68 (s, 2H, CO-
CH=CHCO), 5.14‐5.07 (m, 5H,  HC=C(CH3)), 3.54‐3.49 (t, J = 7.2 Hz, 2H, CH2N), 2.70-2.50 
(m, 2H, CH2CONH), 2.40‐1.90 (m,  20H, =C(CH3)CH2CH2), 1.80 (s, 3H, HC=C(CH3)2), 
1.76‐1.65 (m, 12H, HC=C(CH3)CH2), 1.62‐1.60 (m, 4H, NCH2CH2CH2CH2CH2CON), 1.41‐
1.33 (m, 2H, NCH2CH2CH2CH2CH2CON). 
13
C NMR (CDCl3) δ: 171.2, 166.3, 147.3, 135.8, 
135.7‐132.0, 125.9‐124.7, 42.5, 39.7‐26.4, 38.2, 36.6, 31.0, 26.9, 25.9, 24.6‐16.4, 22.4. MS 
(EI): m/z(%) 81 (70), 110 (100), 192 (55), 591 (3). HPLC analysis: Symmetry C18 column, 5 
m (Merck, Italy) equipped with a C18 column guard, elution with 100% methanol, detection 
by UV adsorption measurement at 237 nm (flow rate 1 mL/min, tr=5.79 min). Peak heights 
were recorded and processed on a CBM-10A Shimadzu interface. 
 
1.3. Synthesis and characterization of the Michael adduct of CKAAKN and 6-
(maleimidyl)-hexanoic acid (trisnor-squalenylidene)-hydrazide (SQ-CKAAKN, (5)) 
 A mixture of (9) (13.5 mg, 0.0229 mmol) and CKAAKN peptide (4) (7.25 mg, 0.0114 
mmol) in dimethylformamide DMF/H2O 3/1 v/v (2 mL) was stirred for 3 h at 40 °C. The 
reaction mixture was then concentrated under reduced pressure and the crude product was 
taken into diethyl ether to remove unreacted maleimide. The supernatant was withdrawn after 
decantation (3 times). In order to eliminate unreacted peptide, the solid was dissolved in 
methanol and filtered through a sintered glass funnel. The product was obtained as a 
translucent waxy material (10 mg, 0.0082 mmol, 70% yield); MS (+ESI): m/z (%) = 1226.0 
(100) [MH]
+
, 614.5 (2) (Fig.1). 
 
1.4. Preparation of nanoparticles  
SQdFdC and SQdFdC/SQCKAAKN nanoparticles were prepared by the nanoprecipitation 
technique [24]. Practically, for SQdFdC NPs, SQdFdC was dissolved in ethanol (40 mg/mL) 
and then added dropwise under magnetic stirring into 1 mL of MilliQ
®
 water (ethanol/water 
0.1/1 v/v). Formation of the nanoparticles occurred spontaneously without using any 
surfactant. After solvent evaporation under reduced pressure, an aqueous suspension of pure 
SQdFdC nanoparticles was obtained (final SQdFdC concentration 4 mg/mL). For 
SQdFdC/SQCKAAKN NPs the two compounds were dissolved in 0.1 mL of ethanol at 1:0.01 
SQdFdC/SQCKAAKN molar ratio. The organic solution was then added dropwise under 
magnetic stirring into 1 mL of MilliQ
®
 water (ethanol/water 0.1/1 v/v). After solvent 
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evaporation under reduced pressure, an aqueous suspension of SQdFdC/SQCKAAKN NPs 
was obtained (final SQdFdC concentration: 3.4 mg/mL).  
Fluorescent nanoparticles were obtained using the same procedure, unless 1% (w/w), of 
the fluorescent probe CholEsteryl BODIPY® FL C12 (BChol-green, Life Technologies, 
Molecular Probes, France) was dissolved in the ethanolic solution before dropwise addition 
into water. Ethanol was evaporated as described above. All the formulations were stored at 
room temperature.  
 
1.5. Nanoparticle characterization 
The mean particle size and polydispersity index of SQdFdC NPs and of 
SQdFdC/SQCKAAKN NPs were measured by dynamic light scattering (DLS) with a Nano 
ZS from Malvern (UK) (173° scattering angle) at 25 °C. The measurements were performed 
after dilution of the NPs suspensions 1:25 in MilliQ
®
 water. The NPs surface charge was 
investigated by zeta potential measurements at 25°C after dilution with 0.05 mM KCl 
solution, applying the Smoluchowski equation and using the same apparatus. Measurements 
were carried out in triplicate. The colloidal stability was investigated by measuring the 
nanoparticle mean diameter over a period of 72 hours (Supplementary material, Figure S2). 
The morphology of the nanoparticles was examined by cryogenic transmission electron 
microscopy (cryoTEM). Briefly, one drop (5 μL) of the nanoparticles suspensions (5 mg/mL) 
was deposited on a 200-mesh electron microscopy grid. Most of the drop was removed with a 
blotting filter paper and the residual thin film remaining within the holes was vitrified by 
plunging it into liquid ethane. The specimen was then transferred using liquid nitrogen to a 
cryo-specimen holder and observed using a JEOL 2100HC microscope.  
 
1.6.  Surface plasmon resonance analysis 
Interaction analyses were performed on a BIAcore T100 instrument including CM5 
Series S sensor chip (GE Healthcare Life Sciences Europe, France). All experiments were 
carried out at 25 °C in Dulbecco-PBS (D-PBS) running buffer. The immobilization process 
was performed with 150 mM phosphate buffer, pH 7.4 at a flow rate of 10 µL/min. The 
carboxymethylated dextran matrix was activated for 7 min with a mixture 1:1 N-ethyl-N’-(3-
diethylaminopropyl)-carbodiimide (EDC) 0.1 M/ N-hydroxysuccinimide (NHS) 0.4M (GE 
Healthcare Life Sciences Europe, France). The sFRP-4 receptor was then injected over the 
activated surface at 10 µg/mL in 10 mM sodium acetate buffer at pH 4.4 during 7 min, giving 
an average immobilization level of 2800 resonance units (RU). Unreacted sites of the matrix 
were finally blocked by a 7-min injection of 1 M ethanolamine hydrochloride at pH 8.5. For 
reference, an additional blank flow channel was prepared according to the same process 
without injecting the receptor over the surface. Binding capacities of the functional surfaces 
were tested with 180 s injections of CKAAKN peptide solution, nanoparticles or 
nanoparticles functionalized with the CKAAKN peptide at different concentrations. All 
experiments were carried out in duplicate on the IPSIT platform (Châtenay-Malabry, France). 
 
1.7. Evaluation of the activation of C3 protein of the complement system 
The activation of the complement system (highlighted by the conversion of plasmatic C3 
protein into C3b and C3a fragments) induced by the different nanoparticles was evaluated by 
2-D immunoelectrophoresis using a polyclonal antibody to human C3 [25]. Human serum was 
obtained after calcifying plasma from healthy donors (EFS Ile-de-France, France) and stored 
at −80 °C until use. Veronal-buffered saline (VBS) containing 0.15 mM Ca2+ and 0.5 mM 
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Mg
2+
 ions (VBS
2+
) and VBS containing 40 mM ethylenediaminetetraacetic acid (VBS–
EDTA) were prepared as described by Kazatchkine et al. [26]  Complement C3 antiserum 
rose in goat was purchased from Sigma-Aldrich (France). To ensure a valid comparison of the 
different nanoparticles, each sample was concentrated up to 6 mg/mL to obtain a sufficient 
specific surface (Sspecif = 6 m/Dd, where m is the mass contained in the sample, D is the 
average diameter and d is the density). 100 µL of nanoparticles (corresponding to an 
equivalent surface area of 167 cm
2
) were incubated under gentle agitation for 1 h at 37 °C 
with 50 μL of human serum and 50 μL of VBS2+. 100 µL of water were used as a control of 
spontaneous activation of C3 protein and 100 µL of redox radical emulsion polymerization 
(RREP) dextran (0.5%)-coated poly(isobutylcyanoacrylate) (PIBCA) nanoparticles [27] were 
used as positive control (Supplementary material, Figure S3). All experiments were 
performed with the same human serum whose functionality was tested before use 
(Supplementary material, Figure S3). After incubation, 7 µL of each sample were subjected to 
a first electrophoresis (600 V, 16 mA, 100 W, 70 min) on 1% agarose gel in tricine buffer, 
then the 2-D electrophoresis (500 V, 12 mA, 100 W, 18 h) was carried out on Gelbond
®
 film 
coated with agarose gel containing a polyclonal antibody to human C3 at 0.1 mg/mL for 
detection of native and activated form of C3. Films were fixed in 0.15 M NaCl, further dried 
and stained with Coomassie blue to reveal the presence of native C3, and lower molecular 
weight activated fragments C3a and C3b precipitated with the antibody. Activation of the C3 
protein was expressed as the complement activation factor (CAF) defined as the ratio of the 
peak surface of C3a+C3b detected on the plate over the sum of the peak surface of C3 and 
C3a+b. For the nanoparticles, the CAF was then normalized (CAFn) on a scale ranging from 0 
to 100 in which 100 indicated total activation and 0 the spontaneous activation measured in 
absence of nanoparticles. Areas under the peaks were measured using ImageJ
®
 software. All 
experiments were set up in triplicate or more to determine means and SD. 
 
1.8. Transgenic tumor model 
The RIP-Tag2 transgenic mouse model has been previously reported [28]. Transgenic 
mice were generated by backcrossing transgenic males with C57Bl/6 females (Jackson 
Laboratory, USA). All animal procedures were approved by the Ethical Commission of the 
University of Turin and by the Italian Ministry of Health in compliance with the international 
laws and policies. 
 
1.9. In vivo therapeutic efficacy 
Tumor-bearing RIP-Tag2 mice were treated for two weeks, starting from 12 until 14 weeks of 
age. Mice were randomized and assigned to 4 groups of 8 mice each and all groups received 
four intravenous injections in the lateral tail vein on days 0, 3, 7 and 11 with either (i) 15 
mg/kg dFdC; (ii) SQdFdC NPs at dFdC equivalent dose of 15 mg/kg; (iii) 
SQdFdC/SQCKAAKN NPs at dFdC equivalent dose of 15 mg/kg or (iv) saline control 
solution. In order to obtain an isosmotic solution, dextrose (5% w/w) was added to the 
nanoparticle suspensions and their colloidal stability was investigated by measuring mean 
diameter (Supplementary material, Figure S2). Mice were monitored regularly for changes in 
weight and health status. Mice were humanely sacrificed on day 12. A pre-treatment with 
5mg/kg of dexamethasone (Decadron
®
, CABER S.p.A., Italy) was performed by 
intramuscular injection 4 h before the treatment. No toxicity of nanoparticles or gemcitabine 
was observed at the dose tested.  
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1.10. Tissue preparation and histology 
Tumor tissues were fresh frozen in Optimum Cutting Temperature (O.C.T. Tissue Tek) 
and cut in 10 µm thick sections using a Leica CM1900 cryostat. Sections were air-dried, fixed 
in zinc fixative (6.05 g Tris, 0.35 g Ca (C2H3O2)2, 2.5 g Zn (C2H3O2)2, 2.5 g ZnCl, 3.8 mL 
HCl 37%) for 10 min and they were blocked with 1% bovine serum albumin and 5% serum 
(donkey serum) in PBS. Tissues were then subjected to immunostaining with the following 
appropriate primary antibodies: purified rat monoclonal anti-Panendothelial cell antigen 
(Meca32) (clone Meca32, BD Pharmingen, USA), diluted 1/100; rabbit polyclonal anti-α-
SMA (Abcam, UK), diluted 1/100; rabbit anti-NG2 (Chondroitin sulphate proteoglycan 
polyclonal) (AB5320, Chemicon), diluted 1:100 rabbit monoclonal anti-cleaved caspase-3 
[29] (asp175, clone 5A1, Cell Signaling, USA), diluted 1/50 or rabbit polyclonal anti-Frizzled 
5 (Abcam, UK) diluted 1/100. The secondary antibodies used were: anti-rabbit Alexa 
Fluor
®
488 or Alexa Fluor
®
555 and anti-rat Alexa Fluor
®
488 or Alexa Fluor
®
555 (1/400, 
Molecular Probes, USA). Nuclei were counterstained with DAPI (Invitrogen, USA). All 
immunofluorescence images were captured by using a Leica TCS SP2 AOBS confocal laser-
scanning microscope (Leica Microsystems) maintaining the same laser power, gain and offset 
settings. All immune-localization experiments were performed on multiple tissue sections and 
included negative controls for determination of background staining, which was negligible. 
 
1.11. In vivo NPs binding 
A cohort of tumor-bearing RIP-Tag2 mice was pretreated with 5mg/kg Decadron for 4 
hours and then alternatively injected with fluorescent SQdFdC NPs or 
SQdFdC/SQCKAAKN NPs. Free CholEsteryl BODIPY
®
 FL C12  dye was used as 
negative control. Mice were sacrificed 6 hours after administration and tissues were 
collected and included freshly in OCT. Vessels were stained with Meca32 antibody and 
nuclei were counterstained with DAPI (as described in 1.10.Tissue preparation and 
histology). Confocal images were scored for the presence of fluorescent SQdFdC NPs or 
SQdFdC/SQCKAAKN NPs in the tumor context. 
 
1.12. Ex vivo targeting and Flow cytometry analysis 
A pool of purified pancreatic insulinomas was obtained from two end-stage RIP-Tag2 
mice. Tissues were mechanically portioned through a McIlwain Tissue Chopper, 
resuspended in serum free L-15 Leibovitz medium (Sigma Aldrich) with 0.25mg 
collagenases B and D (Roche) and incubated for 10 minutes at 37°C under shaking. In 
order to isolate single cells, tissues were further digested in trypsin (Sigma Aldrich) and 
filtered with 70 µm cell strainer (BD Falcon). Samples were resuspended in MACS 
buffer (PBS pH 7.2, FCS 1%, 2mM EDTA) and incubated with 1 µM fluorescently 
labeled SQdFdC NPs, SQdFdC/SQCKAAKN NPs or free CholEsteryl BODIPY
®
 FL 
C12  dye as negative control for 4 hours at 37°C in the dark. After washing with 1x PBS, 
tumor endothelial cells were stained for cytometry by anti-CD31-APC antibody (BD 
Pharmingen), in the dark at 4°C for 30 minutes. Then, samples were washed, 
resuspended in MACS buffer and analyzed on a flow cytometer (CyAn ADP, 
DakoCytomation). 
 
1.13.  Confocal microscopy quantifications 
Quantifications of tumor vasculature were performed with MacBiophotonics ImageJ. The 
total area occupied by vessels was quantified as percentage of Meca32 positive staining on the 
tumor tissue area. For each animal, the total vessel area of 5 fields/mouse was quantified. To 
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quantify pericyte coverage (α-SMA, red channel) in each image, a region of interest (ROI) 
close to each blood vessel (Meca32, green channel) was drawn and then the mean 
fluorescence intensity (MFI) of red and green channels was quantified using the Leica 
Confocal Software Histogram Quantification Tool. The ratio between red and green channel 
MFI was then calculated; values were expressed as percentage of red-green co-staining. To 
determine the expression levels of caspase-3 (red channel) the number of cleaved caspase-3 
positive cells on the total number of cells present in the tissue area was measured in each 
analyzed image. 
 
1.14. Immunohistochemistry analysis 
Frozen tumor sections were processed as previously described in the above “Tissue 
preparation and histology” section. Then, slides were permeabilized in 0.1% PBS, treated for 
30 min with 3% hydrogen peroxide (Sigma-Aldrich, Italy) to quench endogenous peroxidases 
and saturated with protein block serum-free (Dako, Denmark). Tissues were stained with the 
rabbit polyclonal anti-Ki67 (Abcam, UK) primary antibody, diluted 1/100. Anti-rabbit horse 
radish-peroxydase-conjugate secondary antibody (EnVision; DakoCytomation, Denmark) was 
used, and the reaction was visualized with the AEC kit (DakoCytomation). Tissues were 
counterstained with Mayer hematoxylin (Vector Laboratories), mounted on glass slides, and 
visualized with a BX-60 microscope (Olympus) equipped with a color Qicam Fast 1394-
digital CCD camera (12 bit; QImaging). The number of proliferating cells was evaluated by 
using ImageJ and considering 5 different fields/mouse. Values are presented as percent of 
Ki67 positive cells on total cell number. 
 
1.15. Statistical analysis 
The results of all experiments are expressed as mean ± SD. Statistical analyses were 
performed using a 2-tailed, unpaired Mann-Whitney U test. A p value below 0.05 was 
considered significant. 
 
 
 
2. Results and discussion 
 
2.1. Design and characterization of CKAAKN-functionalized nanoparticles 
SQdFdC (3) was synthesized as reported elsewhere [22] by acylation of the C-4 
nitrogen atom of the cytosine nucleus with 1,1’,2- trisnor-squalenic acid (2) prepared from 
squalene (Fig. 1). 
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Fig. 1. Squalenoyl derivatives.  
 
 
The obtained amphiphilic bioconjugate is able to spontaneously self-assemble in water into 
nanoparticles [22]. The thiol group of the N-terminal cysteine of the CKAAKN peptide (4) 
enabled the conjugation of the peptide to squalene, previously modified by the introduction of 
a 6 carbon atom lipophilic chain with a maleimide terminal group, which allowed to establish 
a hydrolysable bond between the squalene moiety and the maleimide group and a relatively 
stable thioether bond between the maleimide group and the peptide (5). In spite of the 
difficulty to allow the highly hydrophilic peptide to react with the lipophilic squalene 
derivative, the thiol-maleimide Michael-type addition allowed to obtain the desired conjugate 
with a satisfactory 70% yield (Supplementary material, Figure S1). Thanks to their similar 
squalenoyl moiety, the simple addition of an ethanolic solution of the two materials (that is, 
SQdFdC/SQCKAAKN in 1/0.01 molar ratio) to water led to the spontaneous formation of 
nanoparticles without requiring any surfactant (ethanol/water 0.1/1 v/v). The obtained 
nanoparticle suspension was characterized by a high drug loading (~ 40%) and a narrow size 
distribution (average diameter of 130-170 nm with polydispersity index of 0.1) as confirmed 
by DLS and cryo-transmission electron microscopy (Fig. 2a,c). 
Interestingly, the higher zeta potential value of SQdFdC/SQCKAAKN NPs, as compared with 
SQdFdC NPs (ZP average of -6 mV vs -22 mV), probably relies to the protonation of the 
lysine amino groups present in the CKAAKN structure, suggesting the presence of the peptide 
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onto the nanoparticle surface which is a crucial aspect to obtain an efficient cancer cell 
targeting.  
 
 
 
Fig. 2. Characterization of SQdFdC and SQdFdC/SQCKAAKN NPs.  
 
 
2.2. Ligand-receptor interaction 
In order to further confirm the surface localization of the CKAAKN peptide and to 
evaluate its targeting ability, the ligand-receptor binding of the peptide was investigated. 
Since it was reported by Joyce et al [20], that the sequence CKA-K shared motifs with the 
Wnt-2 protein, we tested if CKAAKN could act as Wnt-2 mimetic interacting with the 
Frizzled (FZD) receptors, by surface plasmon resonance (SPR). Among the FZD family, we 
focused our attention on the FZD-5 because it has been correlated with the development of 
vascular abnormalities and angiogenesis processes [30, 31].Since the receptor immobilization 
on the SPR biosensor could alter its conformation affecting the ligand binding, we chose to 
use the sFRP-4, a secreted frizzled-related protein with high FZD-5 sequence alignment 
(BLAST analysis) that was already successfully used to this aim keeping its recognition 
ability [32].  
Interestingly, the CKAAKN peptide was able to specifically interact with the sensorchip-
immobilized sFRP-4 confirming the correlation indicated previously (Supplementary 
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material, Figure S4) [20]. Remarkably, a more important plasmonic signal was obtained with 
SQdFdC/SQCKAAKN NPs, whereas no signal was observed under identical experimental 
conditions with non-functionalized SQdFdC NPs (Fig. 3).  
 
 
 
Fig. 3. Surface plasmon resonance analysis of SQdFdC NPs and SQdFdC/SQCKAAKN NPs.  
 
 
 
Moreover, SQdFdC/SQCKAAKN NPs showed a concentration-dependent sensorgram profile 
(Supplementary material, Figure S5). The more important ligand-receptor interaction 
observed with CKAAKN-functionalized nanoparticles, as compared with the free peptide, 
demonstrated that the affinity of phage-display-derivated peptides can be significantly 
enhanced thanks to the multivalent interactions offered by a scaffold-like nanosized material 
in concordance with previous observations [33, 34]. Although peptides present several 
advantages in comparison to other targeting homing devices (i.e., easy of synthesis and low 
immunogenicity), they usually possess modest target affinity. However, the conjugation of 
multiple copies of targeting ligand onto the nanocarrier surface, allows overcoming this 
limitation by enabling multivalent interaction with high binding constants and improving 
targeting efficacy [33]. These results allowed identifying the biological target of the 
CKAAKN peptide confirming also its surface localization.  
The Wnt-2 belongs to a family of secreted lipid-modified signaling glycoproteins principally 
involved in embryonic development and tissue homeostasis [35]. Wnt-signaling pathway has 
also been shown to regulate the pancreatic β-cell endocrine function [36], proliferation, 
migration and differentiation [30]. Comprehensive genetic analysis [37-39] revealed that the 
Wnt is one of the six signaling pathways always altered in pancreatic cancers. [40] Its 
overexpression has recently been correlated to tumorigenesis, driving the self-renewal and 
differentiation of cancer stem cells and promoting the angiogenesis process [12, 35, 39, 41, 
42]. On the basis of these observations, CKAAKN peptide, a specific Wnt-2 mimetic, may be 
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considered as a novel promising homing device to tailor targeted nanoparticle towards 
pancreatic cancer cells.  
 
 
2.3. Complement activation in human serum 
Taken together, these results clearly demonstrated the potential of CKAAKN-functionalized 
squalene-based nanoparticles to specifically interact with the target receptor. However, it has 
been reported that a high ligand density at the nanoparticle surface may promote idiosyncratic 
reactions based on complement activation and lead to a pseudo-allergic reaction (CARPA 
effect), which is responsible for thrombocytopenia, cardiopulmonary and hemodynamic 
changes that could conduce to death [43-45]. Therefore, SQdFdC/SQCKAAKN NPs and 
SQdFdC NPs were investigated for their ability of activating the complement C3 component, 
a key player in the activation of complement system [46]. It was observed that both types of 
NPs were very weak activators of the complement C3 component in human serum. Non-
functionalized and CKAAKN-functionalized nanoparticles displayed, indeed, normalized 
Complement Activating Factor (CAFn) values of 10 ± 2.1% and 10 ± 2.8%, respectively (Fig. 
4). According to the literature [27, 47], SQdFdC NPs and SQdFdC/SQCKAAKN NPs 
displayed low capacity to activate the complement system thus supplementing the 
hypothesis of a safe intravenous administration. 
 
 
 
Fig. 4. Activation of C3 protein of the complement system.  
 
 
2.4. Antitumor efficacy of CKAAKN-functionalized NPs in RIP-Tag2 mice 
 
In the light of these results, we performed a regression trial to assess if 
SQdFdC/SQCKAAKN NPs were more efficient than SQdFdC NPs or dFdC in blocking 
tumor growth and angiogenic process in RIP-Tag2 mice, which were previously used for the 
phage-display screening [20]. RIP-Tag2 mice offer the advantage of both a spontaneous 
tumor development through multistage tumorigenesis and a well-documented angiogenic 
switching, in parallel to cancer progression. This well-characterized mouse model represents a 
suitable and highly reproducible platform to perform pre-clinical trials to test the effects of 
and anti-tumor and anti-angiogenic drug [28, 48-52]. In this work we used RIP-Tag2 mice as 
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proof-of-concept model to assess the ability of SQdFdC/SQCKAAKN NPs to impair tumor 
angiogenesis and, at the same time, to regress the growth of established cancers, Twelve 
week-old tumor-bearing RIP-Tag2 mice were injected intravenously (days 0, 3, 7 and 11) 
with either dFdC (15 mg/kg), SQdFdC NPs (15 mg/kg eq. dFdC) or SQdFdC/SQCKAAKN 
NPs (15 mg/kg eq. dFdC) and compared with saline-treated control mice. All treatments 
induced a significant reduction of the tumor volume compared with saline treated controls. 
SQdFdC NPs reduced tumor burden by 32% compared with dFdC, confirming the superior 
activity of squalenoyl gemcitabine nanoparticles, already demonstrated in other animal tumor 
models [53-55]. Interestingly, SQdFdC/SQCKAAKN NPs displayed a greater efficacy in 
impairing tumor growth compared with SQdFdC NPs (by 40%) and with dFdC (by 60 %) 
(Fig. 5a).  
 
 
 
Fig. 5. Anti-tumor activity and apoptotic index.  
 
 
 
The mechanism underlying the observed anticancer activity of CKAAKN-functionalized NPs 
was further investigated by assessing the proliferation and apoptosis indexes. Despite the fact 
that a significant reduction of cancer cell proliferation (anti-Ki67 Ab immune-staining) was 
observed in all treated groups compared with control (Supplementary material, Figure S6), the 
apoptotic rate (i.e., anti activated caspase-3 immune-staining) was specifically increased in 
both nanoparticles-treated groups compared with dFdC and saline-treated ones (Fig. 5b,c). 
Treatment with NPs increased the apoptotic cell number in tumors by 82% compared with 
both dFdC and control groups. Remarkably, the treatment with SQdFdC/SQCKAAKN NPs 
induced a statistically significant increase (by 44%) in active caspase-3 immunostaining, 
compared with their non functionalized counterpart (Fig. 5c). Noteworthy is that the dramatic 
increase of apoptosis observed in SQdFdC/SQCKAAKN NPs group was detected not only in 
cancer cells but also in the tumor blood vessels (Fig. 5b). To better analyze the potential anti-
angiogenic effect, we further analyzed the tumor vasculature and, by immunostaining with 
Meca-32 antibody and confocal analysis, we observed that SQdFdC/SQCKAAKN NPs 
dramatically reduced the vessel area by 58%, 55% and 57% compared with control, dFdC and 
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non functionalized NPs, respectively (Fig. 6a,b). Next we checked pericytes coverage of 
tumor blood vessels. The quantification of α-smooth muscle actin (α-SMA) 
(Supplementary material, Figure S7) and NG2 co-localized with tumor endothelial cells 
revealed a greater pericyte coverage in SQdFdC/SQCKAAKN NPs-treated animals 
comparatively with SQdFdC NPs, dFdC and saline treated ones (by 40%, 39%  and 
39%, respectively) (Fig. 6c,d). Increased pericyte coverage and reduction in vascular density 
are hallmarks of tumor blood vessel normalization. It has been proposed that the duration of 
the vascular normalization window, that allows more efficient delivery of oxygen and 
chemotherapeutic drugs into the tumor tissue, is critical to achieve a long-lasting and 
successful therapeutic synergy between antiangiogenic and chemotherapeutic drugs [50, 56].  
Taken together, these results suggest that the tumor regression observed with 
CKAAKN-functionalized nanoparticles resulted from a dual activity on both cancer 
cells and tumor vasculature. To consolidate this hypothesis, the tissues of tumor-bearing 
RIP-Tag2 mice were recovered upon injection of fluorescently-labeled NPs. A significant 
increase of SQdFdC/SQCKAAKN NPs accumulation in both tumor vasculature and 
cancer cells was observed compared with both non-functionalized NPs and the control 
(i.e., the free fluorophore) (Figure 7). In addition, FACS analysis of fresh RIP-Tag2 
tumors incubated with fluorescently-labeled NPs further confirmed the strong binding 
of peptide-functionalized NPs to tumor vasculature (tumor vessel/NPs  36% co-staining), 
compared to non-functionalized NPs (tumor vessel/NPs 10% co-staining) 
(Supplementary material, Figure S8). 
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Fig. 6. Immunohistochemical staining of tumor tissue-vessels and pericyte 
quantification. 
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Fig. 7. Immunohistochemical staining of in vivo tumor tissue-vessels targeting by 
SQdFdC/SQCKAAKN NPs and SQdFdC NPs. 
 
 
 
On the basis of previous data indicating the Wnt sharing motifs with the CKAAKN peptide 
[20] and of our data showing the FZD-5 as putative receptor for CKAAKN peptide-
functionalized nanoparticles, we investigated the expression of FZD-5 in RIP-Tag2 tumors. 
Interestingly, we observed by immunostaining a strong expression of FZD-5 in tumor 
vasculature but also, although to a lower extent, in cancer cells of end-stage Rip-Tag2 tumors 
(Fig. 8).  
 
 
 
Fig. 8. Immunocytochemistry analysis and FZD-5 expression in tumor tissue.  
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These results pointed out that the enhanced antitumor activity observed for the CKAAKN-
functionalized squalene-gemcitabine nanoparticles reflects by the multiple ability of (i) 
targeting both tumor and vessel cells, (ii) inhibiting tumor growth and angiogenesis and (iii) 
normalizing the vasculature [51, 52] (Fig. 9).   
 
 
 
Fig. 9. Schematic representation of the selective targeting of pancreatic tumor and multiple 
mechanism of action involved in the enhanced antitumor activity of CKAAKN-functionalized 
squalene-gemcitabine nanoparticles. 
 
 
 
3. Conclusion 
In a nutshell, we propose here a novel, efficient and easy method to prepare peptide-
targeted squalene-based nanoparticles for pancreatic cancer treatment, able to specifically 
interact with both tumor cells and angiogenic vessels and capable of simultaneously 
promoting pericyte coverage, thus leading to the normalization of tumor blood vessels likely 
improving the tumor accessibility for the therapy. The superior efficacy of peptide-decorated 
nanoparticles compared with the non functionalized ones in RIP-Tag2 mice and our studies in 
pancreatic cancer cells suggest that the active targeting plays a key role in the improvement of 
the therapeutic efficacy of gemcitabine in experimental pancreatic cancers.  
To our knowledge, this is the first successful example of pancreatic cancer targeted 
nanoparticles with unique selectivity and multiple mechanism of action. 
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Figure captions 
 
Fig. 1. Squalenoyl derivatives. Structure of dFdC (1), CKAAKN peptide (4) and their 
squalenoyl conjugates SQdFdC (3) and SQCKAAKN (5). 
 
Fig. 2. Characterization of SQdFdC and SQdFdC/SQCKAAKN NPs. Dynamic light 
scattering (DLS) data giving (a) the average diameter in number and (b) the zeta potential 
(ZP) of SQdFdC and SQdFdC/SQCKAAKN NPs. (c) Cryogenic transmission electron 
microscopy of SQdFdC/SQCKAAKN NPs. Scale bar: 100 nm. 
 
Fig. 3. Surface plasmon resonance analysis of SQdFdC and SQdFdC/SQCKAAKN NPs. SPR 
sensorgrams (resonance units (RU) versus time) obtained by simultaneous injection of 
SQdFdC and SQdFdC/SQCKAAKN NPs (180 µM eq. SQ) over sFRP-4 immobilized on two 
parallel channels of the same sensor chip. 
 
Fig. 4. Activation of C3 protein of the complement system. 2D electroimmunophoretic profile 
of complement activation for (a) SQdFdC NPs and (b) SQdFdC/SQCKAAKN NPs.  
 
Fig. 5. Anti-tumor activity and apoptotic index. (a) Total tumor volume in a 2-weeks 
regression trial in RIP-Tag2 mice. Mice were injected intravenously (days 0, 3, 7 and 11) with 
either dFdC (15 mg/kg), SQdFdC NPs (15 mg/kg equiv. dFdC) or SQdFdC/SQCKAAKN 
NPs (15 mg/kg equiv. dFdC) (n=8/group). Tumor volume values (86.08 mm
3
, 45.97 mm
3
, 
31.01 mm
3
 and 18.49 mm
3 
for saline, dFdC, SQdFdC NPs and SQdFdC/SQCKAAKN 
NPs-treated mice, respectively), represent means ± SD. Statistical difference is marked by 
**p < 0.01; ***p < 0.001). (b) Confocal analysis of five fields per mouse from each treatment 
20 
 
group immunostained with Meca32 (green) and cleaved caspase-3 (red). Apoptotic cancer 
cells are indicated with arrow heads and tumor vessels with arrows. Endothelial cells 
apoptotic rate was detected by colocalization of Meca32 (green) with activated caspase-3 
(red). Scale bars: 50 μm. (c) Apoptotic index of cleaved caspase-3+ cells on total cells. Values 
represent mean ± SD. Statistical difference is marked by **p < 0.01.  
 
Fig. 6. Immunohistochemical staining of tumor tissue-vessels and pericyte quantification. (a) 
Representative images (5 fields/mouse) of confocal analysis of Meca32 (green channel) 
endothelial marker immunostaining in tumor tissues from the different groups of treatment. 
Nuclei were stained with DAPI (blue channel). Scale bars: 50 μm. (b) Percentage of surface 
area occupied by vessels quantified as Meca32 positive staining. (c) Quantification analysis of 
NG2 pericyte marker localized in proximity to endothelial cells-lined blood vessels. Values 
represent mean ± SD. Statistical difference is marked by **p < 0.01. (d) Tumor vessel 
pericyte coverage was evaluated as Meca32 (green channel) and NG2 (red channel) 
colocalization. Images are representative of 5 fields per mouse from a total of 8 mice per 
treatment group. Scale bars: 50 μm. 
 
Fig. 7. Representative images of confocal analysis of tumor sections after injection of 
fluorescently-labeled SQdFdC NPs or fluorescently-labeled SQdFdC/SQCKAAKN NPs 
(green channel).Tumor vessels were stained Meca32 (red channel) endothelial marker 
and nuclei with DAPI (blue channel). Free dye was used as negative control. Scale bars: 
50 μm. 
Fig. 8. Immunocytochemistry analysis and FZD-5 expression in tumor tissue. FZD-5 
expression and localization in RIP-Tag2 tumors were assessed by immunofluorescence and 
confocal analysis. FZD-5 expressed on vessels is shown as co-staining of anti-FZD-5 
antibody (red channel) with Meca32 (green channel). Nuclei were stained with DAPI (blue 
channel). The images shown are representative confocal microscopy of 5 fields per mouse. 
Scale bars: 50 μm. 
Fig. 9.Schematic representation of  the selective targeting of pancreatic tumor and multiple 
mechanism of action involved in the enhanced antitumor activity of CKAAKN-functionalized 
squalene-gemcitabine nanoparticles. 
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